Literature DB >> 20298405

Inflammatory phenotypes in adult asthma: clinical applications.

Peter Gerard Gibson1.   

Abstract

BACKGROUND: The pattern of granulocyte infiltration can be used to identify different inflammatory phenotypes in asthma. Recognized granulocyte phenotypes using induced sputum are eosinophilic (EA), neutrophilic, mixed granulocytic and paucigranulocytic asthma.
METHODS: The recognition and importance of inflammatory phenotype analysis using induced sputum in adult asthma are reviewed using published literature.
RESULTS: Knowledge of inflammatory phenotype is useful because it relates to treatment response, mechanistic pathways involved in disease pathogenesis and future disease risk. The population attributable risk of asthma because of eosinophilic inflammation is about 50%, and conversely, this means that up to 50% of asthma cannot be attributed to eosinophilic inflammation, and represents asthma associated with non-eosinophilic processes. In these patients, bronchial biopsy shows significantly fewer eosinophils in the bronchial mucosa than subjects with EA. This confirms that non-eosinophilic asthma is a consistent pattern/phenotype in the airway lumen and the airway mucosa. A key aspect of asthma inflammatory phenotype analysis is that it can be applied to individual patients. The underlying principle relates to the association between a clinical response to corticosteroids and the presence of a selective sputum eosinophilia.
CONCLUSIONS: Clinically useful applications of induced sputum analysis are the detection of non-adherence to corticosteroid therapy, assessment of adequacy of inhaled corticosteroid therapy, long-term therapy management in asthma, oral corticosteroid dose adjustment in refractory asthma and assessment of occupational asthma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20298405     DOI: 10.1111/j.1752-699X.2009.00162.x

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  39 in total

Review 1.  Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials.

Authors:  Prescott G Woodruff
Journal:  Proc Am Thorac Soc       Date:  2011-08

2.  A large subgroup of mild-to-moderate asthma is persistently noneosinophilic.

Authors:  Kelly Wong McGrath; Nikolina Icitovic; Homer A Boushey; Stephen C Lazarus; E Rand Sutherland; Vernon M Chinchilli; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2012-01-20       Impact factor: 21.405

Review 3.  Human asthma phenotypes: from the clinic, to cytokines, and back again.

Authors:  Nirav R Bhakta; Prescott G Woodruff
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

Review 4.  Modeling TH 2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma.

Authors:  Paul S Foster; Steven Maltby; Helene F Rosenberg; Hock L Tay; Simon P Hogan; Adam M Collison; Ming Yang; Gerard E Kaiko; Philip M Hansbro; Rakesh K Kumar; Joerg Mattes
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

5.  Cockroach allergens induce biphasic asthma-like pulmonary inflammation in outbred mice.

Authors:  Louis J Vaickus; Jacqueline Bouchard; Jiyoun Kim; Sudha Natarajan; Daniel G Remick
Journal:  J Asthma       Date:  2012-04-30       Impact factor: 2.515

Review 6.  Eosinophils in mucosal immune responses.

Authors:  J Travers; M E Rothenberg
Journal:  Mucosal Immunol       Date:  2015-03-25       Impact factor: 7.313

7.  Increased Sputum IL-17A Level in Non-asthmatic Eosinophilic Bronchitis.

Authors:  Chen Zhan; Rong Xu; Jiaxing Liu; Shengfang Zhang; Wei Luo; Ruchong Chen; Kefang Lai
Journal:  Lung       Date:  2018-10-01       Impact factor: 2.584

8.  Activated mouse eosinophils protect against lethal respiratory virus infection.

Authors:  Caroline M Percopo; Kimberly D Dyer; Sergei I Ochkur; Janice L Luo; Elizabeth R Fischer; James J Lee; Nancy A Lee; Joseph B Domachowske; Helene F Rosenberg
Journal:  Blood       Date:  2013-12-02       Impact factor: 22.113

9.  Anti-interleukin 5 Therapy for Eosinophilic Asthma: a Meta-analysis of Randomized Clinical Trials.

Authors:  Fa-Ping Wang; Xiao-Feng Xiong; Ting Liu; Su-Yun Li; De-Yun Cheng; Hui Mao
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 10.  The Role and Immunobiology of Eosinophils in the Respiratory System: a Comprehensive Review.

Authors:  Stephanie S Eng; Magee L DeFelice
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.